Xilio Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xilio Therapeutics (XLO).

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingOutperform# Analysts2Avg. Consensus PT$33Upside to Avg. PT+334.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	Raymond James	Sean McCutcheon	Initiate	Outperform	$16
Aug 6, 2025	Leerink Partners	Daina Graybosch	Initiate	Outperform	$28
Nov 8, 2024	Raymond James	Dane Leone	PT Cut	Outperform	$84→$56

Analyst Ratings News

PRO
Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16

Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.

Benzinga Newsdesk

PRO
Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $4

Raymond James analyst Dane Leone maintains Xilio Therapeutics (NASDAQ:XLO) with a Outperform and lowers the price target from $6 to $4.

Benzinga Newsdesk

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

Chardan Capital analyst Matthew Barcus reiterates Xilio Therapeutics (NASDAQ:XLO) with a Buy and maintains $7 price target.

Benzinga Newsdesk

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

Chardan Capital analyst Matthew Barcus reiterates Xilio Therapeutics (NASDAQ:XLO) with a Buy and maintains $7 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10

Morgan Stanley analyst Michael Ulz maintains Xilio Therapeutics (NASDAQ:XLO) with a Overweight and lowers the price target from $20 to $10.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022

Benzinga Insights

Xilio Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Xilio Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16

PRO
Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $4

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PRO
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022

People Also Watch

People Also Watch

Xilio Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Xilio Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORaymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16

PRORaymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $4

PROChardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PROChardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PROMorgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022

People Also Watch

People Also Watch

PRO
Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16

PRO
Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $4

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PRO
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

PRO
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10